Renin Inhibitors

Publisher Website
Google Scholar
Abstract
RENIN INHIBITORSIN the May 4, 1978, issue of the Journal, Gavras et al. reported the first clinical trial of a new agent that promised a different approach to the treatment of hypertension — the inhibition of the renin–angiotensin system.1 Renin, a proteolytic enzyme, is secreted by the juxtaglomerular cells of the kidney. It cleaves angiotensin I from a circulating protein substrate, angiotensinogen. Angiotensin I is in turn cleaved by another protease, converting enzyme, to form the potent pressor hormone, angiotensin II.The drug Gavras et al. tested was captopril, a converting-enzyme inhibitor that prevents the formation of angiotensin . . .